Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03028740 · ClinicalTrials.gov registry record · Phase 3
AURORA: A Study for the Efficacy and Safety of Cenicriviroc (CVC) for the Treatment of Liver Fibrosis in Adults With Nonalcoholic Steatohepatitis (NASH)
A Phase 3 study, sponsored by Tobira Therapeutics.
- Terminated
- Registry status
- Phase 3
- Development phase
- 1,778
- Enrollment target
NCT03028740: Clinical Trial Phase 3 study, sponsored by Tobira Therapeutics.
NCT03028740 is a Phase 3 study that was terminated before completion, run by Tobira Therapeutics. The registered enrollment target is 1,778 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (130% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03028740, a Phase 3 study, was terminated before completion, sponsored by Tobira Therapeutics.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 1,778 participants
- Enrollment target
Study Summary
The AURORA study will be conducted to confirm the efficacy and safety of cenicriviroc (CVC) for the treatment of liver fibrosis in adult participants with NASH.
Primary Outcome
Fibrosis stage was evaluated using the Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN) Fibrosis Staging System with stages: 0=none; 1=perisinusoidal or periportal; 1A=mild, zone 3, perisinusoidal; 1B=moderate, zone 3, perisinusoidal; 1C=portal/periportal; 2=perisinusoidal and portal/periportal; 3=bridging fibrosis; 4=cirrhosis. No worsening of steatohepatitis was defined as no worsening of lobular inflammation or hepatocellular ballooning grade as per scoring in relevant nonalc
Interventions
- DRUG Placebo
- DRUG Cenicriviroc
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,778 participants |
| Start Date | 2017-04-05 |
| Est. Completion | 2021-03-09 |
| Phase | Phase 3 |
Why NCT03028740 stopped before completion
NCT03028740 is an interventional study that assigns participants to a tested intervention. Its 1,778 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (130% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03028740 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03028740 about?
NCT03028740 is a clinical study titled "AURORA: A Study for the Efficacy and Safety of Cenicriviroc (CVC) for the Treatment of Liver Fibrosis in Adults With Nonalcoholic Steatohepatitis (NASH)". The AURORA study will be conducted to confirm the efficacy and safety of cenicriviroc (CVC) for the treatment of liver fibrosis in adult participants with NASH.
What is the current status of trial NCT03028740?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 1,778 participants. The study started on 2017-04-05. Estimated completion is 2021-03-09.
What interventions are being tested in trial NCT03028740?
The interventions under investigation include: Placebo (DRUG), Cenicriviroc (DRUG).
Who is sponsoring clinical trial NCT03028740?
This trial is sponsored by Tobira Therapeutics, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03028740's enrollment target sits among peer trials
1,778 126th of 2000 higher than 1,875 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03067181 · 1,780 participants · Phase 3
Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
- NCT06526650 · 1,780 participants · NA
'Ai Pono Cooking Demonstrations
- NCT05770570 · 1,785 participants · Phase 2
Taxi ROADmAP (Realizing Optimization Around Diet And Physical Activity)
- NCT06239688 · 1,764 participants · NA
Evaluating a National Person-Centered Training Program to Strengthen the Dementia Care Workforce
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI